Teriparatide for osteoporosis: importance of the full course

Co-administration of Antiresorptive and Anabolic Agents: A Missed Opportunity

(2015) Ego Seeman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate

(2015) Felicia Cosman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Teriparatide fracture effectiveness in the real world

(2015) J. H. Krege et al.   OSTEOPOROSIS INTERNATIONAL

Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis

(2015) M. M. Bonafede et al.   OSTEOPOROSIS INTERNATIONAL

Anabolic effects of PTH and the ‘anabolic window’

(2015) Michael Pazianas   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Challenges in longitudinal measurements with HR-pQCT: Evaluation of a 3D registration method to improve bone microarchitecture and strength measurement reproducibility

(2014) Rafaa Ellouz et al.   BONE

Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis

(2014) Erik F. Eriksen et al.   BONE

Cortical Bone: A Challenging Geography

(2014) Roger Zebaze et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial

(2014) Benjamin Z. Leder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

High-resolution in vivo imaging of bone and joints: a window to microarchitecture

(2014) Piet Geusens et al.   Nature Reviews Rheumatology

Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study

(2014) C. Senn et al.   OSTEOPOROSIS INTERNATIONAL

Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy

(2014) B. Hofstetter et al.   OSTEOPOROSIS INTERNATIONAL

PINP as a biological response marker during teriparatide treatment for osteoporosis

(2014) J. H. Krege et al.   OSTEOPOROSIS INTERNATIONAL

Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment

(2013) Yanfei L. Ma et al.   BONE

Teriparatide Treatment of Severe Osteoporosis Reduces the Risk of Vertebral Fractures Compared with Standard Care in Routine Clinical Practice

(2013) Ailsa J. Oswald et al.   CALCIFIED TISSUE INTERNATIONAL

18F-fluoride Positron Emission Tomography Measurements of Regional Bone Formation in Hemodialysis Patients with Suspected Adynamic Bone Disease

(2013) Michelle L. Frost et al.   CALCIFIED TISSUE INTERNATIONAL

Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Pilot Study

(2013) Adi Cohen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results

(2013) S. Silverman et al.   OSTEOPOROSIS INTERNATIONAL

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years

(2012) Elizabeth B Andrews et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee

(2012) David W Dempster et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: An 18-month open-labeled observational study using HR-pQCT

(2012) Stinus Hansen et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial

(2012) David W. Dempster et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges

(2012) D. Bauer et al.   OSTEOPOROSIS INTERNATIONAL

Concise Review: The Periosteum: Tapping into a Reservoir of Clinically Useful Progenitor Cells

(2012) Hana Chang et al.   Stem Cells Translational Medicine

Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis

(2011) JH Krege et al.   BONE

The impact of teriparatide adherence and persistence on fracture outcomes

(2011) S. Yu et al.   OSTEOPOROSIS INTERNATIONAL

Targeted Regeneration of Bone in the Osteoporotic Human Femur

(2011) Kenneth E. S. Poole et al.   PLoS One

Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases

(2010) Akimitsu Miyauchi et al.   BONE

Changes in Cross-Sectional Area of Spinal Canal and Vertebral Body Under 2 Years of Teriparatide Treatment: Results from the EUROFORS Study

(2010) R. Schnell et al.   CALCIFIED TISSUE INTERNATIONAL

Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis

(2010) Joel S. Finkelstein et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis

(2010) J. J. Stepan et al.   OSTEOPOROSIS INTERNATIONAL

Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)

(2010) A. Fahrleitner-Pammer et al.   OSTEOPOROSIS INTERNATIONAL

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

(2010) S. Vasikaran et al.   OSTEOPOROSIS INTERNATIONAL

Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis

(2010) H. M. Macdonald et al.   OSTEOPOROSIS INTERNATIONAL

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial

(2009) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy

(2009) Sarah J. Glover et al.   BONE

Reduction in Fracture Rate and Back Pain and Increased Quality of Life in Postmenopausal Women Treated with Teriparatide: 18-Month Data from the European Forsteo Observational Study (EFOS)

(2009) Bente L. Langdahl et al.   CALCIFIED TISSUE INTERNATIONAL

Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment

(2009) Sven Prevrhal et al.   CURRENT MEDICAL RESEARCH AND OPINION

Improvements in Vertebral Body Strength Under Teriparatide Treatment Assessed In Vivo by Finite Element Analysis: Results From the EUROFORS Study

(2009) Christian Graeff et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated With Alendronate*

(2009) Harald Dobnig et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis*

(2009) Robert R Recker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: Results from the EUROFORS study

(2009) Jan Borggrefe et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Of mice and men: divergent risks of teriparatide-induced osteosarcoma

(2009) V. Subbiah et al.   OSTEOPOROSIS INTERNATIONAL

Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study*

(2008) Helmut Minne et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effects of PTH and Alendronate on Type I Collagen Isomerization in Postmenopausal Women With Osteoporosis: The PaTH Study

(2008) Patrick Garnero et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment

(2008) Barbara M Obermayer-Pietsch et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate

(2008) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis

(2008) R. Lindsay et al.   OSTEOPOROSIS INTERNATIONAL

Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis

(2007) Steven Boonen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM